Is Zydus Wellness overvalued or undervalued?

As of 26 September 2025, Zydus Wellness has moved from a fair to an expensive valuation grade. The company is currently considered overvalued. Key ratios include a PE ratio of 47.60, an EV to EBITDA of 40.53, and a PEG ratio of 8.18, which are significantly higher than the industry average, indicating a premium valuation. In comparison to peers, Zydus Wellness's PE ratio is lower than Hindustan Unilever's 55.46 and Nestle India's 74.54, both of which are also classified as very expensive. Despite this, Zydus's valuation remains elevated relative to its own financial performance, as evidenced by a ROCE of only 6.11% and a ROE of 6.02%. Recent stock performance shows that while Zydus has outperformed the Sensex over the past year with a return of 21.42% compared to the Sensex's -6.30%, this does not justify its current valuation levels.